Analysts expect that Novavax, Inc. (NASDAQ:NVAX) will announce $10.17 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Novavax’s earnings. The highest sales estimate is $11.50 million and the lowest is $9.00 million. Novavax posted sales of $8.35 million in the same quarter last year, which suggests a positive year over year growth rate of 21.8%. The company is expected to issue its next earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Novavax will report full-year sales of $39.07 million for the current fiscal year, with estimates ranging from $36.40 million to $41.50 million. For the next fiscal year, analysts expect that the company will report sales of $25.00 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Novavax.
Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of $10.80 million for the quarter, compared to analyst estimates of $10.02 million. Novavax’s quarterly revenue was up 61.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.16) EPS.
A number of equities analysts have weighed in on the company. B. Riley set a $10.00 price target on Novavax and gave the stock a “buy” rating in a research report on Monday, October 8th. BidaskClub raised Novavax from a “sell” rating to a “hold” rating in a research report on Tuesday, October 2nd. Cantor Fitzgerald set a $2.00 price target on Novavax and gave the stock a “hold” rating in a research report on Wednesday, September 26th. JPMorgan Chase & Co. raised Novavax from an “underweight” rating to an “overweight” rating and boosted their price target for the stock from $2.00 to $2.25 in a research report on Friday, September 21st. Finally, Zacks Investment Research downgraded Novavax from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $3.37.
A number of hedge funds and other institutional investors have recently made changes to their positions in NVAX. Regentatlantic Capital LLC bought a new stake in shares of Novavax during the second quarter worth approximately $107,000. Xact Kapitalforvaltning AB bought a new stake in shares of Novavax during the first quarter worth approximately $119,000. SG Americas Securities LLC boosted its holdings in shares of Novavax by 388.4% during the second quarter. SG Americas Securities LLC now owns 102,003 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 81,117 shares during the period. Suntrust Banks Inc. bought a new stake in shares of Novavax during the first quarter worth approximately $161,000. Finally, Metropolitan Life Insurance Co. NY boosted its holdings in shares of Novavax by 40.9% during the second quarter. Metropolitan Life Insurance Co. NY now owns 137,288 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 39,849 shares during the period. 42.46% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ NVAX traded down $0.06 during trading on Monday, reaching $1.89. 4,035,956 shares of the company’s stock were exchanged, compared to its average volume of 10,087,791. The company has a market cap of $746.05 million, a PE ratio of -3.00 and a beta of 2.62. The company has a quick ratio of 4.52, a current ratio of 4.52 and a debt-to-equity ratio of -3.63. Novavax has a fifty-two week low of $0.96 and a fifty-two week high of $2.75.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.
Further Reading: How does inflation affect different investments?
Get a free copy of the Zacks research report on Novavax (NVAX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.